AbbVie Inc. (ABBV)


Analysis of Solvency Ratios
Quarterly Data

Beginner level


Solvency Ratios (Summary)

AbbVie Inc., solvency ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Debt Ratios
Debt to equity 10.49 7.33 5.65 6.20 7.39 7.95 5.77 6.71 6.87 8.03 6.61 5.65 11.09 8.62 3.18 2.83 3.07
Debt to capital 1.27 1.30 1.27 1.27 1.08 1.10 0.91 0.88 0.85 0.86 0.88 0.89 0.85 0.87 0.87 0.89 0.87 0.85 0.92 0.90 0.76 0.74 0.75
Debt to assets 0.65 0.65 0.65 0.68 0.61 0.60 0.54 0.53 0.55 0.56 0.56 0.56 0.56 0.56 0.59 0.60 0.59 0.58 0.57 0.54 0.52 0.51 0.50
Financial leverage 19.52 13.89 10.29 11.15 13.14 14.26 10.30 11.92 11.57 13.45 11.28 9.78 19.39 15.81 6.13 5.57 6.10

Based on: 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-07), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-20), 10-Q (filing date: 2014-11-07), 10-Q (filing date: 2014-08-07), 10-Q (filing date: 2014-05-09).

Solvency ratio Description The company
Debt to equity ratio A solvency ratio calculated as total debt divided by total shareholders’ equity.
Debt to capital ratio A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. AbbVie Inc.’s debt to capital ratio deteriorated from Q1 2019 to Q2 2019 but then improved from Q2 2019 to Q3 2019 not reaching Q1 2019 level.
Debt to assets ratio A solvency ratio calculated as total debt divided by total assets. AbbVie Inc.’s debt to assets ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Financial leverage ratio A solvency ratio calculated as total assets divided by total shareholders’ equity.

Debt to Equity

AbbVie Inc., debt to equity calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Short-term borrowings —  306  499  3,699  3,002  3,511  367  400  800  400  400  377  —  494  400  406  760  —  569  425  301  251 
Current portion of long-term debt and finance lease obligations 5,276  5,335  1,579  1,609  1,019  3,019  6,014  6,015  3,021  3,020  25  25  26  23  2,023  2,025  4,007  4,021  4,021  22  20  18 
Long-term debt and finance lease obligations, excluding current portion 33,126  31,619  35,066  35,002  36,487  30,579  30,906  30,953  33,974  33,817  36,526  36,440  37,284  37,328  29,490  29,240  31,359  27,116  10,683  10,565  14,469  14,470  14,386 
Total debt 38,402  37,260  37,144  40,310  40,508  37,109  37,287  37,368  37,795  37,237  36,951  36,842  37,310  37,845  31,913  31,671  32,127  31,123  15,273  15,011  14,792  14,741  14,406 
 
Stockholders’ equity (deficit) (8,226) (8,566) (7,826) (8,446) (2,921) (3,376) 3,553  5,097  6,687  6,009  4,998  4,636  6,469  5,640  4,643  3,945  4,863  5,504  1,377  1,742  4,645  5,218  4,697 
Solvency Ratio
Debt to equity1 10.49 7.33 5.65 6.20 7.39 7.95 5.77 6.71 6.87 8.03 6.61 5.65 11.09 8.62 3.18 2.83 3.07
Benchmarks
Debt to Equity, Competitors2
Abbott Laboratories 0.60 0.61 0.62 0.64 0.77 0.68 0.70 0.90 0.75 0.76 0.76 1.07 0.41 0.43 0.41 0.42 0.40 0.38 0.41 0.36 0.36 0.31 0.33
Allergan PLC 0.39 0.38 0.38 0.37 0.33 0.36 0.37 0.41 0.43 0.40 0.42 0.43 0.37 0.52 0.55 0.56 0.55 0.59 0.62 0.55 0.53 1.27 0.91
Amgen Inc. 2.73 2.84 3.05 2.71 2.40 2.31 2.28 1.40 1.11 1.11 1.11 1.16 1.15 1.10 1.20 1.12 1.14 1.16 1.14 1.19 1.30 1.37 1.41
Biogen Inc. 0.43 0.46 0.43 0.46 0.43 0.48 0.42 0.47 0.51 0.56 0.57 0.54 0.54 0.57 0.63 0.70 0.62 0.05 0.05 0.05 0.06 0.06 0.07
Bristol-Myers Squibb Co. 1.41 1.56 0.40 0.52 0.54 0.60 0.60 0.68 0.57 0.56 0.59 0.41 0.44 0.45 0.47 0.47 0.48 0.49 0.48 0.53 0.51 0.50 0.49
Eli Lilly & Co. 4.50 5.68 6.44 1.30 0.97 1.06 0.81 1.18 0.90 0.87 0.73 0.74 0.60 0.64 0.54 0.55 0.53 0.55 0.55 0.52 0.32 0.30 0.29
Gilead Sciences Inc. 1.19 1.15 1.21 1.28 1.19 1.34 1.41 1.64 1.18 1.16 1.29 1.39 1.60 1.42 1.70 1.20 1.28 0.75 0.72 0.80 0.69 0.59 0.73
Johnson & Johnson 0.50 0.48 0.50 0.51 0.48 0.51 0.51 0.57 0.48 0.48 0.46 0.39 0.37 0.36 0.32 0.28 0.28 0.27 0.28 0.27 0.20 0.22 0.23
Merck & Co. Inc. 0.97 0.96 0.94 0.94 0.73 0.72 0.70 0.71 0.71 0.63 0.71 0.62 0.57 0.56 0.59 0.59 0.58 0.57 0.63 0.44 0.62 0.48 0.56
Pfizer Inc. 0.81 0.78 0.77 0.66 0.58 0.58 0.56 0.61 0.72 0.75 0.75 0.71 0.70 0.70 0.62 0.60 0.58 0.53 0.53 0.51 0.48 0.49 0.48
Regeneron Pharmaceuticals Inc. 0.07 0.07 0.08 0.08 0.09 0.10 0.11 0.11 0.12 0.13 0.15 0.11 0.09 0.09 0.10 0.10 0.12 0.12 0.16 0.18 0.22 0.22 0.24

Based on: 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-07), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-20), 10-Q (filing date: 2014-11-07), 10-Q (filing date: 2014-08-07), 10-Q (filing date: 2014-05-09).

1 Q3 2019 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity (deficit)
= 38,402 ÷ -8,226 =

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to equity ratio A solvency ratio calculated as total debt divided by total shareholders’ equity.

Debt to Capital

AbbVie Inc., debt to capital calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Short-term borrowings —  306  499  3,699  3,002  3,511  367  400  800  400  400  377  —  494  400  406  760  —  569  425  301  251 
Current portion of long-term debt and finance lease obligations 5,276  5,335  1,579  1,609  1,019  3,019  6,014  6,015  3,021  3,020  25  25  26  23  2,023  2,025  4,007  4,021  4,021  22  20  18 
Long-term debt and finance lease obligations, excluding current portion 33,126  31,619  35,066  35,002  36,487  30,579  30,906  30,953  33,974  33,817  36,526  36,440  37,284  37,328  29,490  29,240  31,359  27,116  10,683  10,565  14,469  14,470  14,386 
Total debt 38,402  37,260  37,144  40,310  40,508  37,109  37,287  37,368  37,795  37,237  36,951  36,842  37,310  37,845  31,913  31,671  32,127  31,123  15,273  15,011  14,792  14,741  14,406 
Stockholders’ equity (deficit) (8,226) (8,566) (7,826) (8,446) (2,921) (3,376) 3,553  5,097  6,687  6,009  4,998  4,636  6,469  5,640  4,643  3,945  4,863  5,504  1,377  1,742  4,645  5,218  4,697 
Total capital 30,176  28,694  29,318  31,864  37,587  33,733  40,840  42,465  44,482  43,246  41,949  41,478  43,779  43,485  36,556  35,616  36,990  36,627  16,650  16,753  19,437  19,959  19,103 
Solvency Ratio
Debt to capital1 1.27 1.30 1.27 1.27 1.08 1.10 0.91 0.88 0.85 0.86 0.88 0.89 0.85 0.87 0.87 0.89 0.87 0.85 0.92 0.90 0.76 0.74 0.75
Benchmarks
Debt to Capital, Competitors2
Abbott Laboratories 0.38 0.38 0.38 0.39 0.43 0.40 0.41 0.47 0.43 0.43 0.43 0.52 0.29 0.30 0.29 0.30 0.28 0.28 0.29 0.27 0.27 0.24 0.25
Allergan PLC 0.28 0.28 0.28 0.27 0.25 0.26 0.27 0.29 0.30 0.29 0.30 0.30 0.27 0.34 0.35 0.36 0.36 0.37 0.38 0.35 0.35 0.56 0.48
Amgen Inc. 0.73 0.74 0.75 0.73 0.71 0.70 0.69 0.58 0.53 0.53 0.53 0.54 0.53 0.52 0.54 0.53 0.53 0.54 0.53 0.54 0.57 0.58 0.58
Biogen Inc. 0.30 0.31 0.30 0.31 0.30 0.33 0.30 0.32 0.34 0.36 0.36 0.35 0.35 0.36 0.39 0.41 0.38 0.04 0.05 0.05 0.05 0.06 0.06
Bristol-Myers Squibb Co. 0.59 0.61 0.28 0.34 0.35 0.37 0.38 0.40 0.36 0.36 0.37 0.29 0.30 0.31 0.32 0.32 0.33 0.33 0.32 0.35 0.34 0.34 0.33
Eli Lilly & Co. 0.82 0.85 0.87 0.57 0.49 0.51 0.45 0.54 0.47 0.47 0.42 0.42 0.37 0.39 0.35 0.35 0.35 0.35 0.36 0.34 0.24 0.23 0.22
Gilead Sciences Inc. 0.54 0.54 0.55 0.56 0.54 0.57 0.59 0.62 0.54 0.54 0.56 0.58 0.62 0.59 0.63 0.54 0.56 0.43 0.42 0.45 0.41 0.37 0.42
Johnson & Johnson 0.33 0.33 0.33 0.34 0.33 0.34 0.34 0.37 0.32 0.32 0.32 0.28 0.27 0.27 0.24 0.22 0.22 0.21 0.22 0.21 0.17 0.18 0.18
Merck & Co. Inc. 0.49 0.49 0.48 0.48 0.42 0.42 0.41 0.42 0.41 0.39 0.42 0.38 0.36 0.36 0.37 0.37 0.37 0.36 0.39 0.31 0.38 0.32 0.36
Pfizer Inc. 0.45 0.44 0.43 0.40 0.37 0.37 0.36 0.38 0.42 0.43 0.43 0.41 0.41 0.41 0.38 0.38 0.37 0.34 0.35 0.34 0.32 0.33 0.32
Regeneron Pharmaceuticals Inc. 0.06 0.07 0.07 0.07 0.08 0.09 0.10 0.10 0.10 0.11 0.13 0.10 0.08 0.08 0.09 0.09 0.11 0.10 0.14 0.15 0.18 0.18 0.19

Based on: 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-07), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-20), 10-Q (filing date: 2014-11-07), 10-Q (filing date: 2014-08-07), 10-Q (filing date: 2014-05-09).

1 Q3 2019 Calculation
Debt to capital = Total debt ÷ Total capital
= 38,402 ÷ 30,176 = 1.27

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to capital ratio A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. AbbVie Inc.’s debt to capital ratio deteriorated from Q1 2019 to Q2 2019 but then improved from Q2 2019 to Q3 2019 not reaching Q1 2019 level.

Debt to Assets

AbbVie Inc., debt to assets calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Short-term borrowings —  306  499  3,699  3,002  3,511  367  400  800  400  400  377  —  494  400  406  760  —  569  425  301  251 
Current portion of long-term debt and finance lease obligations 5,276  5,335  1,579  1,609  1,019  3,019  6,014  6,015  3,021  3,020  25  25  26  23  2,023  2,025  4,007  4,021  4,021  22  20  18 
Long-term debt and finance lease obligations, excluding current portion 33,126  31,619  35,066  35,002  36,487  30,579  30,906  30,953  33,974  33,817  36,526  36,440  37,284  37,328  29,490  29,240  31,359  27,116  10,683  10,565  14,469  14,470  14,386 
Total debt 38,402  37,260  37,144  40,310  40,508  37,109  37,287  37,368  37,795  37,237  36,951  36,842  37,310  37,845  31,913  31,671  32,127  31,123  15,273  15,011  14,792  14,741  14,406 
 
Total assets 59,441  57,142  56,769  59,352  66,164  61,641  69,342  70,786  68,840  66,994  65,664  66,099  66,626  67,211  53,720  53,050  54,832  53,855  26,699  27,547  28,454  29,045  28,657 
Solvency Ratio
Debt to assets1 0.65 0.65 0.65 0.68 0.61 0.60 0.54 0.53 0.55 0.56 0.56 0.56 0.56 0.56 0.59 0.60 0.59 0.58 0.57 0.54 0.52 0.51 0.50
Benchmarks
Debt to Assets, Competitors2
Abbott Laboratories 0.28 0.28 0.28 0.29 0.33 0.30 0.31 0.37 0.33 0.34 0.34 0.42 0.22 0.22 0.22 0.22 0.20 0.20 0.21 0.19 0.20 0.18 0.19
Allergan PLC 0.24 0.24 0.24 0.23 0.22 0.23 0.24 0.25 0.25 0.24 0.25 0.25 0.23 0.30 0.31 0.31 0.30 0.31 0.32 0.30 0.29 0.48 0.39
Amgen Inc. 0.50 0.52 0.52 0.51 0.51 0.51 0.50 0.44 0.45 0.44 0.44 0.45 0.45 0.44 0.46 0.44 0.44 0.45 0.44 0.45 0.47 0.48 0.48
Biogen Inc. 0.22 0.23 0.22 0.23 0.23 0.25 0.23 0.25 0.28 0.30 0.31 0.28 0.30 0.30 0.32 0.33 0.32 0.03 0.04 0.04 0.04 0.05 0.05
Bristol-Myers Squibb Co. 0.43 0.45 0.17 0.21 0.22 0.23 0.23 0.24 0.25 0.25 0.26 0.20 0.20 0.21 0.21 0.21 0.23 0.23 0.22 0.23 0.23 0.23 0.23
Eli Lilly & Co. 0.40 0.41 0.42 0.29 0.28 0.29 0.26 0.30 0.31 0.30 0.27 0.27 0.25 0.26 0.23 0.22 0.22 0.22 0.23 0.22 0.16 0.15 0.15
Gilead Sciences Inc. 0.42 0.41 0.42 0.43 0.42 0.44 0.44 0.48 0.45 0.44 0.46 0.46 0.48 0.44 0.48 0.43 0.44 0.31 0.32 0.36 0.33 0.30 0.35
Johnson & Johnson 0.19 0.19 0.20 0.20 0.20 0.21 0.21 0.22 0.23 0.23 0.22 0.19 0.19 0.19 0.17 0.15 0.15 0.15 0.15 0.14 0.12 0.13 0.13
Merck & Co. Inc. 0.31 0.32 0.31 0.30 0.28 0.27 0.27 0.28 0.29 0.27 0.29 0.26 0.26 0.25 0.26 0.26 0.26 0.26 0.28 0.22 0.27 0.24 0.26
Pfizer Inc. 0.31 0.30 0.29 0.26 0.24 0.25 0.25 0.25 0.26 0.26 0.26 0.25 0.25 0.26 0.24 0.23 0.23 0.22 0.22 0.22 0.22 0.22 0.22
Regeneron Pharmaceuticals Inc. 0.05 0.05 0.06 0.06 0.07 0.07 0.08 0.08 0.08 0.09 0.09 0.07 0.06 0.06 0.06 0.06 0.08 0.09 0.11 0.12 0.15 0.15 0.16

Based on: 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-07), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-20), 10-Q (filing date: 2014-11-07), 10-Q (filing date: 2014-08-07), 10-Q (filing date: 2014-05-09).

1 Q3 2019 Calculation
Debt to assets = Total debt ÷ Total assets
= 38,402 ÷ 59,441 = 0.65

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to assets ratio A solvency ratio calculated as total debt divided by total assets. AbbVie Inc.’s debt to assets ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Financial Leverage

AbbVie Inc., financial leverage calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Total assets 59,441  57,142  56,769  59,352  66,164  61,641  69,342  70,786  68,840  66,994  65,664  66,099  66,626  67,211  53,720  53,050  54,832  53,855  26,699  27,547  28,454  29,045  28,657 
Stockholders’ equity (deficit) (8,226) (8,566) (7,826) (8,446) (2,921) (3,376) 3,553  5,097  6,687  6,009  4,998  4,636  6,469  5,640  4,643  3,945  4,863  5,504  1,377  1,742  4,645  5,218  4,697 
Solvency Ratio
Financial leverage1 19.52 13.89 10.29 11.15 13.14 14.26 10.30 11.92 11.57 13.45 11.28 9.78 19.39 15.81 6.13 5.57 6.10
Benchmarks
Financial Leverage, Competitors2
Abbott Laboratories 2.15 2.16 2.19 2.20 2.33 2.24 2.26 2.47 2.26 2.25 2.26 2.56 1.90 1.93 1.91 1.94 1.98 1.92 1.97 1.92 1.86 1.76 1.78
Allergan PLC 1.61 1.60 1.59 1.56 1.51 1.53 1.55 1.60 1.67 1.66 1.69 1.69 1.60 1.73 1.76 1.77 1.84 1.92 1.95 1.85 1.83 2.66 2.33
Amgen Inc. 5.45 5.50 5.91 5.31 4.69 4.54 4.56 3.17 2.49 2.51 2.54 2.60 2.54 2.50 2.62 2.55 2.57 2.59 2.60 2.68 2.79 2.85 2.95
Biogen Inc. 1.96 2.03 1.91 1.94 1.85 1.95 1.86 1.88 1.79 1.88 1.85 1.88 1.82 1.89 2.00 2.08 1.96 1.33 1.30 1.32 1.31 1.35 1.34
Bristol-Myers Squibb Co. 3.25 3.44 2.29 2.49 2.47 2.65 2.59 2.86 2.30 2.27 2.28 2.08 2.16 2.20 2.22 2.23 2.11 2.11 2.16 2.27 2.21 2.19 2.16
Eli Lilly & Co. 11.20 13.91 15.32 4.47 3.41 3.67 3.05 3.88 2.89 2.90 2.68 2.77 2.41 2.49 2.31 2.44 2.39 2.46 2.39 2.42 1.96 1.95 1.90
Gilead Sciences Inc. 2.87 2.79 2.86 2.98 2.81 3.02 3.18 3.44 2.60 2.66 2.82 3.02 3.36 3.22 3.57 2.80 2.91 2.40 2.23 2.25 2.13 1.94 2.10
Johnson & Johnson 2.67 2.55 2.54 2.56 2.41 2.47 2.48 2.61 2.10 2.12 2.06 2.01 1.93 1.93 1.88 1.88 1.86 1.86 1.89 1.88 1.72 1.73 1.74
Merck & Co. Inc. 3.10 3.04 2.99 3.09 2.63 2.61 2.56 2.56 2.40 2.35 2.42 2.38 2.25 2.23 2.25 2.28 2.22 2.21 2.27 2.02 2.25 2.02 2.17
Pfizer Inc. 2.62 2.62 2.64 2.51 2.35 2.36 2.25 2.41 2.83 2.89 2.89 2.88 2.82 2.72 2.58 2.59 2.56 2.40 2.39 2.37 2.20 2.25 2.21
Regeneron Pharmaceuticals Inc. 1.33 1.35 1.36 1.34 1.37 1.38 1.43 1.43 1.44 1.47 1.61 1.57 1.52 1.52 1.57 1.53 1.57 1.36 1.41 1.52 1.47 1.46 1.47

Based on: 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-07), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-20), 10-Q (filing date: 2014-11-07), 10-Q (filing date: 2014-08-07), 10-Q (filing date: 2014-05-09).

1 Q3 2019 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity (deficit)
= 59,441 ÷ -8,226 =

2 Click competitor name to see calculations.

Solvency ratio Description The company
Financial leverage ratio A solvency ratio calculated as total assets divided by total shareholders’ equity.